Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Clin Exp Immunol ; 178(3): 459-69, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25046553

ABSTRACT

In areas without newborn screening for severe combined immunodeficiency (SCID), disease-defining infections may lead to diagnosis, and in some cases, may not be identified prior to the first year of life. We describe a female infant who presented with disseminated vaccine-acquired varicella (VZV) and vaccine-acquired rubella infections at 13 months of age. Immunological evaluations demonstrated neutropenia, isolated CD4 lymphocytopenia, the presence of CD8(+) T cells, poor lymphocyte proliferation, hypergammaglobulinaemia and poor specific antibody production to VZV infection and routine immunizations. A combination of whole exome sequencing and custom-designed chromosomal microarray with exon coverage of primary immunodeficiency genes detected compound heterozygous mutations (one single nucleotide variant and one intragenic copy number variant involving one exon) within the IL7R gene. Mosaicism for wild-type allele (20-30%) was detected in pretransplant blood and buccal DNA and maternal engraftment (5-10%) demonstrated in pretransplant blood DNA. This may be responsible for the patient's unusual immunological phenotype compared to classical interleukin (IL)-7Rα deficiency. Disseminated VZV was controlled with anti-viral and immune-based therapy, and umbilical cord blood stem cell transplantation was successful. Retrospectively performed T cell receptor excision circle (TREC) analyses completed on neonatal Guthrie cards identified absent TREC. This case emphasizes the danger of live viral vaccination in severe combined immunodeficiency (SCID) patients and the importance of newborn screening to identify patients prior to high-risk exposures. It also illustrates the value of aggressive pathogen identification and treatment, the influence newborn screening can have on morbidity and mortality and the significant impact of newer genomic diagnostic tools in identifying the underlying genetic aetiology for SCID patients.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Chickenpox/etiology , Lymphopenia/etiology , Mutation , Receptors, Interleukin-7/genetics , Rubella/etiology , Severe Combined Immunodeficiency/genetics , Vaccination/adverse effects , DNA Copy Number Variations , Exome , Female , Humans , Infant , Oligonucleotide Array Sequence Analysis , Severe Combined Immunodeficiency/immunology
2.
Clin Exp Immunol ; 174(1): 89-96, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23763437

ABSTRACT

Chronic granulomatous disease (CGD) patients are highly susceptible to invasive aspergillosis and might benefit from aspergillus-specific T cell immunotherapy, which has shown promise in treating those with known T cell defects such as haematopoietic stem cell transplant (HSCT) recipients. But whether such T cell defects contribute to increased risks for aspergillus infection in CGD is unclear. Hence, we set out to characterize the aspergillus-specific T cell response in CGD. In murine CGD models and in patients with CGD we showed that the CD4(+) T cell responses to aspergillus were unimpaired: aspergillus-specific T cell frequencies were even elevated in CGD mice (P < 0·01) and humans (P = 0·02), compared to their healthy counterparts. CD4-depleted murine models suggested that the role of T cells might be redundant because resistance to aspergillus infection was conserved in CD4(+) T cell-depleted mice, similar to wild-type animals. In contrast, mice depleted of neutrophils alone or neutrophils and CD4(+) T cells developed clinical and pathological evidence of pulmonary aspergillosis and increased mortality (P < 0·05 compared to non-depleted animals). Our findings that T cells in CGD have a robust aspergillus CD4(+) T cell response suggest that CD4(+) T cell-based immunotherapy for this disease is unlikely to be beneficial.


Subject(s)
Aspergillosis, Allergic Bronchopulmonary/immunology , Aspergillosis, Allergic Bronchopulmonary/therapy , Granulomatous Disease, Chronic/immunology , Granulomatous Disease, Chronic/therapy , Immunotherapy, Adoptive , T-Lymphocytes/immunology , T-Lymphocytes/microbiology , Animals , Aspergillus fumigatus/immunology , Cell Line , Cells, Cultured , Humans , Immunotherapy, Adoptive/methods , Membrane Glycoproteins/deficiency , Membrane Glycoproteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , NADPH Oxidase 2 , NADPH Oxidases/deficiency , NADPH Oxidases/genetics , T-Lymphocytes/pathology , Th1 Cells/immunology , Th1 Cells/microbiology , Th1 Cells/transplantation
3.
Pediatr Infect Dis J ; 20(6): 602-6, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11419503

ABSTRACT

BACKGROUND: The Pediatric Spectrum of HIV Diseases (PSD) project has been collecting data on HIV-exposed children in Texas since 1989. These data have now been analyzed to describe mother-to-child transmission in Texas and to provide much needed information on the magnitude of the pediatric HIV epidemic in the state. METHODS: We examined trends in the numbers of perinatally exposed children and perinatally acquired cases of HIV in the Texas PSD cohort. We calculated transmission rates and relative risks for 656 children born from January, 1995, to July, 1998, that received all or part of the ACTG 076 regimen. RESULTS: Only a small proportion (38%) of pairs of an HIV-infected mother and her HIV-exposed child received the full AIDS Clinical Trial Group 076 (ACTG 076) regimen; only 73% of the mothers received at least some prenatal care. In recent years, however, the numbers of perinatally exposed children and perinatally acquired cases of HIV have decreased in Texas. Univariate analyses showed that a reduction in the vertical transmission of HIV was associated with receipt of a full ACTG 076 regimen, receipt of a partial ACTG 076 regimen and residence in Dallas County. CONCLUSIONS: Findings identify a gap in meeting the health care needs of pregnant HIV-infected women and suggest missed opportunities to prevent mother-to-child transmission of HIV. At the same time this study confirms progress in prevention efforts to reduce mother-to-child transmission of HIV in Texas.


Subject(s)
HIV Infections/transmission , Infectious Disease Transmission, Vertical , Anti-HIV Agents/therapeutic use , Female , HIV Infections/epidemiology , HIV Infections/prevention & control , Humans , Infant, Newborn , Infectious Disease Transmission, Vertical/prevention & control , Male , Pregnancy , Pregnancy Complications, Infectious , Prenatal Care , Risk Factors , Texas/epidemiology , Zidovudine/therapeutic use
4.
Pediatr Clin North Am ; 47(1): 109-25, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10697644

ABSTRACT

The clinical manifestations of HIV disease in children affect multiple organ systems. The severity of each manifestation varies by organ system and can be related in many cases to multifactorial causes, namely HIV replication in affected tissue, concomitant opportunistic infection of the organ, effect of concurrent immunodeficiency or autoimmune mechanisms on the organ, or adverse end-organ drug effect (primary HIV therapy or prophylaxis regimens). More information is needed to understand the pathogenesis of the systemic effect of HIV on different organ systems, especially the CNS. Most clinicians hope that advances in therapeutic interventions for primary HIV will halt the progression of the organ-specific manifestations that have been outlined in this article, but such potent therapies will probably have their own unique and new effects on HIV-infected organ systems. Vigilance for organ-specific manifestations in the era of HAART is imperative to provide the best clinical outcome for HIV-infected children.


Subject(s)
HIV Infections/diagnosis , AIDS-Related Opportunistic Infections , Cardiomyopathies/virology , Child , Female , Gastrointestinal Diseases/virology , HIV Infections/classification , HIV Infections/transmission , Hematologic Diseases/virology , Hepatomegaly , Humans , Infectious Disease Transmission, Vertical , Lymphatic Diseases/virology , Pregnancy , Pregnancy Complications, Infectious
5.
Pediatrics ; 105(1): e8, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10617745

ABSTRACT

BACKGROUND: Infants with perinatally acquired human immunodeficiency virus type 1 (HIV-1) infection have widely variable courses. Previous studies showed that a number of maternal and infant factors, when analyzed separately, are associated with infant HIV-1 disease progression. In this study, clincal, virologic, and immunologic characteristics in the mothers and infants were examined together to determine the predictors of disease progression by 18 months of age and the associations with rapid progression during the first 6 months of life. METHODS: One hundred twenty-two HIV-1-infected women whose infants were HIV-1 infected were identified from the Women and Infants Transmission Study (WITS) cohort. WITS is a longitudinal natural history study of perinatal HIV-1 infection carried out in 6 sites in the continental United States and in Puerto Rico. The women were enrolled during pregnancy and their infants were enrolled at the time of delivery and followed prospectively by a standardized protocol. Virologic and immunologic studies were performed in laboratories certified by National Institutes of Health-sponsored quality assurance programs. Maternal factors in pregnancy were used as potential predictors of infant disease progression (progression to Centers for Disease Control and Prevention [CDC] Clinical Class C disease or death by 18 months of age) or as correlates of progression at <6 months of age. Infant factors defined during the first 6 months of life were used as potential predictors of progression during 6 to 18 months of age and as correlates of progression at <6 months of age. RESULTS: Progression by 18 months of age occurred in 32% of infants and by 6 months of age in 15%. Maternal characteristics that, by univariate analysis, were significant predictors of infant disease progression by 18 months of age were elevated viral load, depressed CD4(+)%, and depressed vitamin A. CD8(+)%, CD8(+) activation markers, zidovudine (ZDV) use, hard drug use, and gestational age at delivery were not. When examined in a combined multivariate analysis of maternal characteristics, only vitamin A concentration independently predicted infant progression. Infant characteristics during the first 6 months of life that, by univariate analysis, were associated with disease progression included elevated mean viral load at 1 to 6 months of age, depressed CD4(+)%, CDC Clinical Disease Category B, and growth delay. Early HIV-1 culture positivity (<48 hours), CD8(+)%, CD8(+) activation markers, and ZDV use during the first month of life did not predict progression. Multivariate analysis of infant characteristics showed that the only independent predictors were progression to CDC Category B by 6 months of age (odds ratio [OR], 5.80) and mean viral load from 1 to 6 months of age (OR, 1.99). The final combined maternal and infant analysis included the significant maternal and infant characteristics in a multivariate analysis. It showed that factors independently predicting infant progression by 18 months of age were progression to CDC Category B by 6 months of age (OR, 5.80) and elevated mean HIV-1 RNA copy number at 1 to 6 months of age (OR, 1.99). The characteristics associated with rapid progression to CDC Category C disease or death by 6 months of age were also examined. The only maternal characteristic associated with progression by 6 months in multivariate analysis was low maternal CD4(+)%. The infant characteristics associated with progression by 6 months of age in multivariate analysis were depressed mean CD4(+)% from birth through 2 months and the presence of lymphadenopathy, hepatomegaly, or splenomegaly by 3 months. Infant ZDV use was not assocciated with rapid progression. CONCLUSION: The strongest predictors of progression by 18 months are the presence of moderate clinical symptoms and elevated RNA copy number in the infants in the first 6 months of life. In contrast, progression by 6 months is associated with maternal and infant immun


Subject(s)
HIV Infections , HIV-1 , Analysis of Variance , CD4 Lymphocyte Count , Disease Progression , Female , HIV Infections/mortality , HIV Infections/transmission , Humans , Infant , Infectious Disease Transmission, Vertical , Logistic Models , Longitudinal Studies , Pregnancy , Pregnancy Complications, Infectious/virology , Risk Factors , Viral Load
6.
Article in English | MEDLINE | ID: mdl-10225228

ABSTRACT

Zidovudine (ZDV) therapy during pregnancy and to the neonate reduced perinatal HIV transmission by nearly 70% in Pediatric AIDS Clinical Trials Group (PACTG) protocol 076. ZDV has been reported as positive in several in vitro carcinogenicity screening tests. We evaluated the short-term risk for tumors in 727 children with known ZDV exposure enrolled into the PACTG 076/219 and the Women and Infants Transmission Study (WITS). ZDV exposure in utero (antepartum) occurred in 97% and 99% of infants in PACTG 076/219 or WITS, respectively. Mean follow-up was 38.3 months with 366.9 person years follow-up for PACTG 076/219 and 14.5 months with 743.7 person years follow-up for WITS. No tumors of any nature were observed; relative risk was 0 (95% confidence interval [CI], 0-17.6). These data are reassuring regarding the short-term lack of tumors for ZDV-exposed infants observed to date. Longitudinal, standardized follow-up for infants with in utero antiretroviral exposure is necessary to assess long-term carcinogenicity.


Subject(s)
Anti-HIV Agents/therapeutic use , Antimetabolites, Antineoplastic/therapeutic use , HIV Infections/drug therapy , HIV Infections/physiopathology , HIV-1 , Neoplasms/prevention & control , Reverse Transcriptase Inhibitors/therapeutic use , Zidovudine/therapeutic use , Female , Follow-Up Studies , HIV Infections/transmission , Humans , Infant , Infant, Newborn , Infectious Disease Transmission, Vertical , Male , Perinatal Care , Pregnancy , Prospective Studies
7.
J Virol ; 73(5): 3975-85, 1999 May.
Article in English | MEDLINE | ID: mdl-10196293

ABSTRACT

Host immunologic factors, including human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL), are thought to contribute to the control of HIV type 1 (HIV-1) replication and thus delay disease progression in infected individuals. Host immunologic factors are also likely to influence perinatal transmission of HIV-1 from infected mother to infant. In this study, the potential role of CTL in modulating HIV-1 transmission from mother to infant was examined in 11 HIV-1-infected mothers, 3 of whom transmitted virus to their offspring. Frequencies of HIV-1-specific human leukocyte antigen class I-restricted CTL responses and viral epitope amino acid sequence variation were determined in the mothers and their infected infants. Maternal HIV-1-specific CTL clones were derived from each of the HIV-1-infected pregnant women. Amino acid substitutions within the targeted CTL epitopes were more frequently identified in transmitting mothers than in nontransmitting mothers, and immune escape from CTL recognition was detected in all three transmitting mothers but in only one of eight nontransmitting mothers. The majority of viral sequences obtained from the HIV-1-infected infant blood samples were susceptible to maternal CTL. These findings demonstrate that epitope amino acid sequence variation and escape from CTL recognition occur more frequently in mothers that transmit HIV-1 to their infants than in those who do not. However, the transmitted virus can be a CTL susceptible form, suggesting inadequate in vivo immune control.


Subject(s)
HIV Infections/immunology , HIV-1/immunology , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious/immunology , T-Lymphocytes, Cytotoxic/immunology , Base Sequence , Cell Line, Transformed , DNA, Viral , Epitopes, T-Lymphocyte/immunology , Female , Genetic Variation , HIV Infections/transmission , HIV Infections/virology , HIV-1/classification , HIV-1/genetics , Histocompatibility Antigens Class I/immunology , Humans , Molecular Sequence Data , Pregnancy , Pregnancy Complications, Infectious/virology
8.
J Infect Dis ; 179(2): 319-28, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9878014

ABSTRACT

In a prospective cohort study, clinical and biologic factors that contribute to maternal-child transmission of human immunodeficiency virus type 1 (HIV-1) were studied. HIV-infected pregnant women and their infants were evaluated prospectively according to a standardized protocol. Of 204 evaluable women, 81% received zidovudine during their pregnancy. The infection rate among the 209 evaluable infants was 9.1%. By univariate analysis, histologic chorioamnionitis, prolonged rupture of membranes, and a history of genital warts were significantly associated with transmission. Additional factors associated with transmission that approached significance included a higher maternal virus load at delivery and the presence of cocaine in the urine. In a logistic regression model, histologic chorioamnionitis was the only independent predictor of transmission. Despite a significantly higher transmission rate at one site, no unique viral genotype was found at any site. Thus, chorioamnionitis was found to be the major risk factor for transmission among women receiving zidovudine.


Subject(s)
Acquired Immunodeficiency Syndrome/transmission , HIV-1 , Infectious Disease Transmission, Vertical , Acquired Immunodeficiency Syndrome/drug therapy , Adult , Cohort Studies , Female , Fetal Blood/virology , HIV-1/classification , Humans , Infant, Newborn , Multivariate Analysis , Phylogeny , Placenta/pathology , Placenta/virology , Pregnancy , Prospective Studies , Risk Factors , Vagina/virology
9.
Pediatrics ; 102(4): E46, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9755283

ABSTRACT

OBJECTIVE: Sexual transmission of human immunodeficiency virus (HIV) is the predominant risk exposure among adolescents and adults reported with HIV infection and acquired immunodeficiency syndrome (AIDS). Although perinatal transmission accounts for the majority of HIV infection in children, there have been reports of HIV transmission through sexual abuse of children. We characterized children <13 years of age who may have acquired HIV infection through sexual abuse. METHODS: All reports by state and local health departments to the national HIV/AIDS surveillance system of children with HIV infection not AIDS (n = 1507) and AIDS (n = 7629) through December 1996 were reviewed for history of sexual abuse. Information was ascertained from data recorded on the case report form as well as investigations of children with no risk for HIV infection reported or identified on initial investigation. For children with a possible history of sexual abuse, additional data were collected, including how sexual abuse was diagnosed; characteristics of the perpetrator(s) (ie, HIV status and HIV risks); and other possible risk factors for the child's HIV infection. RESULTS: Of 9136 children reported with HIV or AIDS, 26 were sexually abused with confirmed (n = 17) or suspected (n = 9) exposure to HIV infection; mean age of these children at diagnosis of HIV infection was 8.8 years (range, 3 to 12 years). There were 14 females and 3 males who had confirmed sexual exposure to an adult male perpetrator at risk for or infected with HIV; of these, 14 had no other risk for HIV infection, and 3 had multiple risks for HIV infection (ie, through sexual abuse, perinatal exposure, and physical abuse through drug injection). The other 9 children (8 females, 1 male) had no other risk factors for HIV infection and were suspected to have been infected through sexual abuse, but the identity, HIV risk, or HIV status of all the perpetrator(s) was not known. All cases of sexual abuse had been reported to local children's protective agencies. Sexual abuse was established on the basis of physician diagnosis or physical examination (n = 20), child disclosure (n = 15), previous or concurrent noncongenital sexually transmitted disease (n = 9), and for confirmed cases, criminal prosecution of the HIV-infected or at-risk perpetrator (n = 8). For the 17 children with confirmed sexual exposure to HIV infection, 19 male perpetrators were identified who were either known to be HIV infected (n = 18) or had risk factors for HIV infection (n = 17), most of whom were a parent or relative. CONCLUSIONS: These 26 cases highlight the tragic intersection of child sexual abuse and the HIV epidemic. Although the number of reported cases of sexual transmission of HIV infection among children is small, it is a minimum estimate based on population-based surveillance and is an important and likely underrecognized public health problem. Health care providers should consider sexual abuse as a possible means of HIV transmission, particularly among children whose mothers are HIV-antibody negative and also among older HIV-infected children. The intersection of child abuse with the HIV epidemic highlights the critical need for clinicians and public health professionals to be aware of the risk for HIV transmission among children who have been sexually abused, and of guidelines for HIV testing among sexually abused children, and to evaluate and report such cases.


Subject(s)
Child Abuse, Sexual , HIV Infections/transmission , Acquired Immunodeficiency Syndrome/transmission , Adult , Child , Child, Preschool , Fatal Outcome , Female , Humans , Male , Population Surveillance , Risk Factors , United States
10.
Pediatr Infect Dis J ; 17(5): 391-7, 1998 May.
Article in English | MEDLINE | ID: mdl-9613652

ABSTRACT

BACKGROUND: Immunocompromise caused by HIV-1 infection increases the importance of receipt of routine childhood vaccines to prevent infections such as invasive Haemophilus influenzae type B (Hib) disease. The objectives of the study were to evaluate the immunogenicity of Hib conjugate vaccines among HIV-infected children according to clinical and immunologic disease progression as well as viral load. METHODS: The concentration of antibody to polyribosylribitol phosphate (PRP) was measured at approximately 9 and 24 months of age in plasma specimens from children of HIV-infected women enrolled in the Women and Infants Transmission Study. RESULTS: Among 227 children (35 HIV-infected, 192 uninfected) at the 9-month study visit who were known to have received age-appropriate immunization with CRM197 mutant Corynebacterium diphtheriae protein-conjugated Hib vaccine, geometric mean antibody concentrations were lower among HIV-infected children (1.64 microg/ml) than among uninfected children (2.70 microg/ml), although the difference was not statistically significant. Anti-PRP antibody concentrations did not vary significantly among these HIV-infected children with predominantly mild-moderate disease progression according to clinical category, immunologic stage or viral load (P > or = 0.48). The proportion of children with antibody concentrations > or = 1.0 microg/ml did not vary significantly according to HIV infection status (73% uninfected, 74% infected) or, if infected, clinical or immunologic disease progression or viral load. Similar results were obtained among 127 children (17 HIV-infected, 110 uninfected) eligible for analysis at the 24-month study visit. Changes in antibody concentrations over time (between 9 and 24 months of age) did not differ significantly among 10 HIV-infected as compared with 72 uninfected children (P=0.81). CONCLUSIONS: These results suggest that HIV-infected children with predominantly mild-moderate disease progression respond reasonably well in terms of a quantitative antibody response to Hib conjugate vaccines during the first 2 years of life. Research to further characterize the immune response to Hib conjugate vaccines and to further delineate the "durability" of anti-PRP antibody concentrations beyond 2 years of life should be pursued.


Subject(s)
Antibodies, Bacterial/isolation & purification , HIV Infections , Haemophilus Vaccines/immunology , Haemophilus influenzae/immunology , Antigens, Bacterial/immunology , Child, Preschool , Female , HIV Seronegativity , HIV Seropositivity , Haemophilus Vaccines/administration & dosage , Humans , Immunocompromised Host , Infant , Pentosephosphates/immunology , Polysaccharides, Bacterial/immunology , Vaccines, Conjugate/administration & dosage , Vaccines, Conjugate/immunology , Viral Load
11.
J Allergy Clin Immunol ; 100(5): 707-11, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9389303

ABSTRACT

BACKGROUND: Available information suggests that IgE levels are elevated in adults infected with human immunodeficiency virus (HIV), and that increased IgE levels correlate with allergic disease, with decreased CD4 counts, and with a poor prognosis. Data with respect to these factors in children are scant. OBJECTIVE: We investigated whether serum IgE levels are elevated in children with HIV and, if so, whether the serum IgE level correlates with the degree of immunodeficiency and/or objective indicators of allergic disease. METHODS: Serum IgE levels, CD4 counts, absolute eosinophil counts, and immediate hypersensitivity skin test (IHST) results were collected from 43 children with symptomatic HIV infection (mean age 7.2 years). Associations between serum IgE levels, CD4 counts, and eosinophil counts were investigated by multiple stepwise linear regression analysis. Data were stratified according to IHST positivity, and analysis of variance was used to compare mean values for age, CD4 counts, IgE levels, and eosinophil counts between the two groups. RESULTS: Serum IgE values were elevated more than 2 SDs above control age-matched mean values in 17 of 43 patients (40%). IHST results were positive in 12 of 43 patients (28%). CD4 counts were less than 200/mm3 in 17 of 43 patients (40%). Stepwise linear regression failed to demonstrate any correlation between serum IgE levels and either CD4 or eosinophil counts. With data divided into two groups according to IHST results (positive vs negative), analysis of variance failed to reveal significant differences between means for patient age, CD4 counts, IgE levels, or eosinophil counts. CONCLUSIONS: Our findings confirm that serum IgE levels are increased in children infected with HIV, just as in adults. However, an elevated serum IgE level did not correlate with allergic disease as measured by IHST results and eosinophil counts, nor with the degree of immune dysfunction as approximated by CD4 counts. The mechanism and significance of elevated serum IgE levels remain unclear in children with HIV, and warrant further investigation.


Subject(s)
HIV Infections/immunology , Acquired Immunodeficiency Syndrome/complications , Adolescent , Adult , CD4-Positive T-Lymphocytes/cytology , Child , Child, Preschool , Eosinophilia/complications , Female , HIV Infections/blood , HIV Infections/complications , Humans , Hypersensitivity/epidemiology , Hypersensitivity/immunology , Immunoglobulin E/blood , Incidence , Linear Models , Lymphocyte Count , Male , Respiratory Hypersensitivity/epidemiology
12.
J Infect Dis ; 176(2): 414-20, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9237706

ABSTRACT

To determine if hepatitis C virus (HCV) infection affects vertical transmission of human immunodeficiency virus (HIV), 487 HIV-infected pregnant women in the prospective, multicenter, Women and Infants Transmission Study had HCV antibody (anti-HCV by second-generation ELISA) and HCV RNA (by quantitative polymerase chain reaction) measured in peripartum maternal plasma; 161 (33%) were anti-HCV-positive. HIV vertical transmission occurred from 42 HCV-infected mothers (26.1%) versus 53 HCV-uninfected mothers (16.3%; odds radio [OR], 1.82; P = .01). In a logistic regression model that included maternal drug use, a potential confounder, HCV infection was marginally associated with perinatal HIV transmission (OR, 1.64; P = .05), whereas drug use was not. Women who transmitted HIV had higher levels of HCV RNA (median, 721,254 copies/mL) than those who did not (337,561 copies/mL; P = .01). Maternal HCV infection is associated with increased HIV vertical transmission. Further studies are needed to ascertain if HCV directly affects perinatal HIV transmission or is a marker for another factor, such as maternal drug use.


Subject(s)
HIV Infections/transmission , HIV-1 , Hepatitis C/complications , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious/virology , Adult , Anti-HIV Agents/therapeutic use , Female , HIV Antibodies/blood , HIV Infections/complications , HIV Infections/drug therapy , HIV-1/immunology , Hepacivirus/genetics , Hepacivirus/isolation & purification , Humans , Infant, Newborn , Multivariate Analysis , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Prospective Studies , RNA, Viral/blood , Risk Factors , Zidovudine/therapeutic use
13.
Health Educ Res ; 12(3): 355-62, 1997 Sep.
Article in English | MEDLINE | ID: mdl-10174218

ABSTRACT

The current US immunization rates for 2 year olds are approximately half of the goal set for the year 2000. Research studies have focused primarily on the perception of health care providers in the identification of barriers and benefits to childhood immunization. While health care providers are an important part of the immunization delivery process, the perceptions of parents are also important. In this study, qualitative methods were used to explore perceived parental barriers to childhood immunization delivery. Twelve focus groups comprising White, African-American, Hispanic, urban and non-urban people were conducted at a variety of sites, including clinics, churches, schools and work sites. The results indicated that time off from work, access to well-child care and difficulty understanding the complexity of the immunization schedule were seen as barriers to adhering to an immunization schedule. Participants emphasized problems in taking time off from work to get immunizations, sometimes without pay, and expressed fears that doing so would jeopardize promotions and raises. While some of the parental perceptions were similar to those identified in studies of health care providers in the literature, many were not. This study emphasizes the importance of gathering information from parents as well as from health care providers.


Subject(s)
Attitude to Health , Health Services Accessibility , Immunization Programs , Parents , Urban Health , Child, Preschool , Female , Focus Groups , Humans , Infant , Male , United States
14.
Acta Paediatr Suppl ; 421: 33-8, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9240855

ABSTRACT

In light of new evidence suggesting that maternal human immunodeficiency virus (HIV) infection produces at least a three-fold increase in the number of early spontaneous abortions, it is important to search for factors that may predispose to fetal wastage. Immunological factors are thought to play an important role in permitting the HLA-disparate fetus to continue to term, despite powerful maternal immune forces capable of rejection. In the context of a heightened incidence of spontaneous abortion in HIV infection, evidence is now accumulating that implicates an imbalance in immune factors in contributing to this fetal loss. Soluble immune factors, such as cytokines, have been suggested as contributing agents to recurrent spontaneous abortions. Inflammatory cytokines-interleukin 1beta, interleukin 6 and tumor necrosis factor alpha-have been measured in isolated placental trophoblastic cells in HIV-infected and non-infected pregnant women in an attempt to explore this hypothesis. These inflammatory cytokines and their messenger RNAs were significantly elevated before and after stimulation in HIV-infected women, supporting the belief that HIV-infected women present their fetuses a milieu of imbalanced immune factors capable of contributing to immunological rejection. In addition, these elevated inflammatory cytokine levels may contribute to HIV disease progression in fetuses by virtue of activation of HIV gene transcription factors similar to what has been demonstrated in in vitro systems. We therefore propose that HIV infection in pregnant women produces an altered state of certain soluble immune factors, which in concert with other immune factor abnormalities, such as loss of immune selection in the fetal thymus, predisposes the fetus to advanced HIV infection and possible spontaneous abortion.


Subject(s)
Cytokines/physiology , HIV Infections/physiopathology , HIV Infections/transmission , Infectious Disease Transmission, Vertical , Placenta/immunology , Pregnancy Complications, Infectious/physiopathology , Abortion, Spontaneous/immunology , Cytokines/biosynthesis , Female , HIV/genetics , HIV Infections/immunology , Humans , Inflammation/physiopathology , Pregnancy , Pregnancy Complications, Infectious/immunology , RNA, Viral/analysis , Trophoblasts/physiology , Up-Regulation/physiology
15.
Acta Paediatr Suppl ; 421: 60-4, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9240860

ABSTRACT

The thymus is thought to play a major role in the immunopathogenesis of human immunodeficiency virus (HIV) infection, particularly in maternal-to-fetal HIV transmission. Characteristic lesions of the HIV-infected thymus include a prominent CD4+ CD8+ T lymphocyte depletion at the corticomedullary junction, the region of the thymus where immune selection occurs. At least threefold excess early spontaneous abortions were noted in a cohort of 124 HIV-infected pregnant women. In these 13 abortuses a very high rate (54%) of HIV vertical transmission was documented, with the thymus gland particularly affected. It is possible that the thymic insult in HIV-infected fetuses contributes to immune rejection of the fetus, possibly by an imbalance of maternal and fetal T1- and T2-type cytokines, known to be important in HIV disease progression. We propose, therefore, that the early spontaneous abortions occurring in HIV-infected pregnant women are due, at least in part, to abnormal immune forces created by HIV infection of the thymus.


Subject(s)
Abortion, Spontaneous/immunology , Fetal Diseases/immunology , HIV Infections/immunology , HIV Infections/transmission , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious/immunology , Thymus Gland/abnormalities , Thymus Gland/immunology , Abortion, Spontaneous/etiology , Female , Fetal Diseases/pathology , Gestational Age , HIV Infections/pathology , Humans , Pregnancy , Pregnancy Complications, Infectious/pathology , Thymus Gland/pathology
16.
J Virol ; 71(2): 1256-64, 1997 Feb.
Article in English | MEDLINE | ID: mdl-8995649

ABSTRACT

Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) are thought to exert immunologic selection pressure in infected persons, yet few data regarding the effects of this constraint on viral sequence variation in vivo, particularly in the highly variable Env protein, are available. In this study, CD8+ HIV type 1 (HIV-1) envelope-specific CTL clones specific for gp120 were isolated from peripheral blood mononuclear cells of four HIV-infected individuals, all of which recognized the same 25-amino-acid (aa) peptide (aa 371 to 395), which is partially contained in the CD4-binding domain of HIV-1 gp120. Fine mapping studies revealed that two of the clones optimally recognized the 9-aa sequence 375 to 383 (SFNCGGEFF), while the two other clones optimally recognized the epitope contained in the overlapping 9-aa sequence 376 to 384 (FNCGGEFFY). Lysis of target cells by the two clones recognizing aa 375 to 383 was restricted by HLA B15 and Cw4, respectively, whereas both clones recognizing aa 376 to 384 were restricted by HLA A29. Sequence variation, relative to the IIIB strain sequence used to identify CTL clones, was observed in autologous viruses in the epitope-containing region in all four subjects. However, poorly recognized autologous sequence variants were predominantly seen for the A29-restricted clones, whereas the clones specific for SFNCGGEFF continued to recognize the predominant autologous sequences. These results suggest that the HLA profile of an individual may not only be important in determining the specificity of CTL recognition but may also affect the ability to recognize virus variants and suppress escape from CTL recognition. These results also identify overlapping viral CTL epitopes which can be presented by HLA A, B, and C molecules.


Subject(s)
Epitopes , HIV Envelope Protein gp120/immunology , HLA-A Antigens/immunology , HLA-B Antigens/immunology , HLA-C Antigens/immunology , T-Lymphocytes, Cytotoxic/immunology , Cytotoxicity, Immunologic , Epitope Mapping , Epitopes/genetics , HIV Envelope Protein gp120/genetics , Humans , Sequence Analysis
18.
Tex Med ; 92(3): 66-71, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8820261

ABSTRACT

Immunization prevalence rates in Houston/Harris County for children 18 to 24 months were determined by a prospective immunization survey conducted from January through May 1993. Rates for immunization series were very low for 2-year old children regardless of infant gender, maternal age, maternal education, or immunization provider (public verus private). African-American infants had the lowest likelihood of completing their immunization series. Infants who had received their first immunization within the scheduled time frame were most likely to complete the series. More than 57% of caregivers could not state accurately the immunization status of their children. Barriers to immunizations perceived by caregivers were identified as medical barriers, vaccine cost, and transportation. New goals for infant immunization delivery have been established by the national Comprehensive Children's Immunization Initiative. To meet these goals, large urban centers like Houston/Harris County must use resources through both public and private sectors, ie, networked, confidential immunization tracking system; enhanced and sustained educational efforts; and expansion of vaccine availability.


Subject(s)
Immunization/statistics & numerical data , Adult , Caregivers/psychology , Delivery of Health Care/standards , Delivery of Health Care/statistics & numerical data , Female , Humans , Infant , Odds Ratio , Prevalence , Prospective Studies , Random Allocation , Risk Factors , Texas/epidemiology
19.
AIDS ; 10(3): 273-82, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8882667

ABSTRACT

OBJECTIVE: To evaluate the relationship of drug use with maternal HIV culture positivity at delivery and perinatal HIV transmission. DESIGN: Multicenter prospective cohort study. SETTING: Obstetric and pediatric clinics in five cities in the United States. PARTICIPANTS: Five hundred and thirty HIV-infected pregnant women and their infants. MAIN OUTCOME MEASURES: Multivariate logistic regression was used to evaluate the association of 'hard drug' use (one or more of the following: cocaine, heroin/opiates, methadone, injecting drug use) assessed by self-report and urine toxicology with positive maternal HIV culture at delivery and perinatal HIV transmission. RESULTS: Forty-two per cent of women used hard drugs during pregnancy. Increased probability of a positive maternal delivery HIV culture was significantly associated with prenatal hard drug use [odds ratio (OR), 3.08] and maternal cocaine use (OR, 2.98) among HIV-infected women with > 29% CD4+ lymphocytes. After adjusting for maternal culture positivity at delivery, CD4+ lymphocyte percentage and gestational age, significantly greater transmission risk was observed with hard drug use among women with membrane rupture > 4 h. CONCLUSIONS: On the basis of self-report and urine toxicology, overall maternal hard drug use and cocaine use in the WITS cohort were associated with maternal HIV culture positivity at delivery, and maternal hard drug use was associated with perinatal transmission.


Subject(s)
HIV Infections/transmission , HIV-1/isolation & purification , Infectious Disease Transmission, Vertical , Pregnancy Complications, Infectious , Substance-Related Disorders/complications , Alcohol Drinking , Cocaine , Cohort Studies , Female , HIV Infections/complications , Heroin , Humans , Infant , Infant, Newborn , Marijuana Smoking , Methadone , Pregnancy , Prospective Studies , Smoking
20.
J Infect Dis ; 172(6): 1451-60, 1995 Dec.
Article in English | MEDLINE | ID: mdl-7594702

ABSTRACT

A prospective study of transplacental transmission of human immunodeficiency virus (HIV) showed an increased rate of spontaneous fetal demise in HIV-seropositive mothers: 14 losses in 124 pregnancies. HIV was detected in placental and fetal tissues in 7 of 14 by in situ hybridization. The proportion of fetal infection far exceeded the transmission rate of 13% in liveborn babies. No association was seen between fetal transmission and a maternal history of drug abuse or coinfections; mothers with AIDS more often had fetal loss associated with HIV transmission than did asymptomatic mothers. In affected fetuses, HIV was detected in many tissues and was associated with thymic pathology. This suggests that maternal HIV infection increases the risk for pregnancy loss associated with HIV transmission. The possibility that HIV may be fetotoxic, that thymic dysfunction may interfere with pregnancy progression, or that the intrauterine milieu in HIV-seropositive pregnancies may be unfavorable (or a combination of factors) should be considered.


Subject(s)
Fetal Death/etiology , HIV Infections/complications , Pregnancy Complications, Infectious , Adolescent , Adult , Child , Female , Humans , Infectious Disease Transmission, Vertical , Pregnancy , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...